注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Aadi Bioscience Inc是一家商業階段的生物製藥公司,該公司致力於開發基因定義癌症的精準療法。該公司的主要重點是為具有雷帕黴素機制靶點(mTOR)通路驅動改變的癌症患者開發治療方法,例如TSC1或TSC2基因改變。該公司最初的重點是治療一種超罕見的癌症血管周圍上皮樣細胞瘤(PEComa)。該公司的主導產品FYARROTM是一種與人白蛋白結合的mTOR抑製劑,在臨床前模型中與其他mTOR抑製劑相比,具有腫瘤積累、mTOR靶點抑制和腫瘤生長抑製作用。FYARRO是一種mTOR抑製劑,適用於治療患有晚期不可切除或轉移性血管周圍上皮樣細胞瘤(PEComa)的成年患者。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Pravin U. Dugel | 57 | 2017 | Independent Director |
Michael T. Lotze | 69 | - | Member of Scientific Advisory Board |
Steven Prelack | 64 | 2017 | Independent Chairman |
Peter A. Campochiaro | - | - | Member of Scientific Advisory Board & Ophthalmology Advisory Board |
Christopher D. Kontos | - | - | Member of Scientific Advisory Board |
Dietmar Vestweber | - | - | Member of Scientific Advisory Board |
Anupam Dalal | 49 | 2011 | Independent Director |
Caley M. Castelein | 50 | 2017 | Independent Director |
Cheryl L. Cohen | 55 | 2018 | Independent Director |
David S. Boyer | - | - | Member of Ophthalmology Advisory Board |
Samir M. Parikh | - | - | Member of Scientific Advisory Board |
Peter K. Kaiser | - | - | Member of Ophthalmology Advisory Board |
Joseph H. Gardner | 65 | 2011 | Founder, President, Principal Executive Officer & Director |
Jeffrey S. Heier | 60 | - | Member of Ophthalmology Advisory Board |
W. Daniel Stamer | - | - | Member of Scientific Advisory Board |
Emma Reeve | 63 | 2021 | Independent Director |
Mohammad Hirmand | 54 | 2023 | Independent Director |
Anupam Dalal | 52 | 2021 | Independent Director |
Neil P. Desai | 59 | 2011 | Founder, Secretary & Executive Chairman |
David J. Lennon | 53 | 2023 | President, CEO & Director |
Richard Maroun | 69 | 2017 | Independent Director |
Behzad Aghazadeh | 53 | 2021 | Independent Director |
Karin M. Hehenberger | 52 | 2021 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核